Meeting NewsVideo

VIDEO: Improved physical function for patients with RA when switched from adalimumab to sarilumab

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Gerd R. Burmester, MD, spoke about the efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of the MONARCH trial.

Burmester said results showed that patients with rheumatoid arthritis had improved physical function when switched from adalimumab 40 mg monotherapy to sarilumab 200 mg every 2 weeks. Additionally, the researchers found the safety profile for this open-label extension trial was consistent with the safety profile found in the MONARCH trial.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Gerd R. Burmester, MD, spoke about the efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of the MONARCH trial.

Burmester said results showed that patients with rheumatoid arthritis had improved physical function when switched from adalimumab 40 mg monotherapy to sarilumab 200 mg every 2 weeks. Additionally, the researchers found the safety profile for this open-label extension trial was consistent with the safety profile found in the MONARCH trial.

    See more from American College of Rheumatology Annual Meeting